Our Scientific Focus
Apellis is dedicated to improving the lives of individuals living with serious disease driven by complement and supports medical and scientific research that demonstrates the highest level of scientific integrity, inclusion, and curiosity.
Hematology
Paroxysmal nocturnal hemoglobinuria (PNH)
- Treatment transition strategies and dosing strategies
- Safety and efficacy in specific subpopulations
- Biomarkers in clinical management
- Quality of Life (QoL) and effect on Activities of Daily Living (ADL)
- Longer-term treatment effects
- Biomarkers of disease severity
- Epidemiology of PNH
- Further characterization and measurement of PNH symptoms (e.g., brain fog)
- Screening for PNH in risk groups
Nephrology
Immune complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G)
- Further disease characterization in patients with either IC-MPGN or C3G
- Biomarkers of disease severity and disease progression in patients with IC-MPGN/C3G
- Novel clinical study endpoints of disease severity and disease progression in IC-MPGN/C3G
- Role of innate immune system in patients with IC-MPGN/C3G
Ophthalmology
Geographic Atrophy (GA)
- Development of tests to evaluate visual function in patients with GA
- Relationship between neovascularization AMD (nAMD) and the development of GA
- Real world effectiveness of pegcetacoplan in patients with GA due to AMD
- Effectiveness and safety of pegcetacoplan in patients with GA due to AMD with clinical features (phenotypes) not assessed in clinical trials (including but not limited to: bilateral GA patients treated in both eyes; GA patients with lesions approximately 200 microns or further from the foveal center)
- Effectiveness and safety of pegcetacoplan in GA patients with different dosing intervals and dose escalation or de-escalation